Windtree Therapeutics reports Q4 2023 net loss of $5.2M; cash only $4.3M as of Dec 31

WINDTREE THERAPEUTICS INC /DE/

Q4 net loss $5.2M ($0.95 per share) vs $9.7M ($13.01) in Q4 2022; FY net loss $20.3M ($5.24 per share).
Cash and equivalents $4.3M at Dec 31, 2023; completed $1.5M convertible note bridge in April 2024 to fund operations through April.
Acquired novel aPKCi inhibitor platform from Varian Biopharmaceuticals; includes topical and oral formulations.
Licensed istaroxime and other CV assets to Lee's Pharmaceutical for Greater China; eligible for up to $138M milestones plus royalties.
Two Phase 2 istaroxime trials in cardiogenic shock ongoing; data expected H2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On April 17, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

499 earnings releases filed in the last 30 days. Browse all earnings releases →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-24-012242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.